Concepedia

Bert Kwanten

BK

Statistics

Publications

2

Citations

137

H-Index

2

Active since

2018

Affiliations

Rega Institute for Medical Research(Current)

KU Leuven

Karyopharm Therapeutics (United States)

Bert Kwanten is an author at Rega Institute for Medical Research specializing in oncology, crispr-based engineering, and drug resistance mutations.

ORCID

Publications per year

2018–2023

2

Publications

2

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Jasper E. Neggers, Bert Kwanten, Tim Dierckx et al. · Nature Communications · 2018 · 105 citations · Full text

, , +17

E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1

Bert Kwanten, Tine Deconick, Christopher J. Walker et al. · Biomedicine & Pharmacotherapy · 2023 · 32 citations · Full text

, , +16

1–2 of 2